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Background: The proportion of clinical research sponsored by industry will likely continue to expand as federal
funds for academic research decreases, particularly in the fields of HIV/AIDS and hepatitis C (HCV). While HIV and
HCV continue to burden the US population, insufficient data exists as to how industry sponsorship affects clinical
trials involving these infectious diseases. Debate exists about whether pharmaceutical companies undertake more
market-driven research practices to promote therapeutics, or instead conduct more rigorous trials than their
non-industry counterparts because of increased resources and scrutiny. The ClinicalTrials.gov registry, which allows
investigators to fulfill a federal mandate for public trial registration, provides an opportunity for critical evaluation of
study designs for industry-sponsored trials, independent of publication status. As part of a large public policy effort,
the Clinical Trials Transformation Initiative (CTTI) recently transformed the ClinicalTrials.gov registry into a searchable
dataset to facilitate research on clinical trials themselves.
Methods: We conducted a cross-sectional analysis of 477 HIV and HCV drug treatment trials, registered with
ClinicalTrials.gov from 1 October 2007 to 27 September 2010, to study the relationship of study sponsorship with
randomized study design. The likelihood of using randomization given industry (versus non-industry) sponsorship
was reported with prevalence ratios (PR). PRs were estimated using crude and stratified tabular analysis and Poisson
regression adjusting for presence of a data monitoring committee, enrollment size, study phase, number of study
sites, inclusion of foreign study sites, exclusion of persons older than age 65, and disease condition.
Results: The crude PR was 1.17 (95% CI 0.94, 1.45). Adjusted Poisson models produced a PR of 1.13 (95% CI 0.82, 1.56).
There was a trend toward mild effect measure modification by study phase, but this was not statistically significant. In
stratified tabular analysis the adjusted PR was 1.14 (95% CI 0.78, 1.68) among phase 2/3 trials and 1.06 (95% CI 0.50, 2.22)
among phase 4 trials.
Conclusions: No significant relationship was found between industry sponsorship and use of randomization in trial
design in this cross-sectional study. Prospective studies evaluating other aspects of trial design may shed further
light on the relationship between industry sponsorship and appropriate trial methodology.
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Over the past 15 years, the proportion of clinical research
sponsored by the pharmaceutical industry has increased
and likely will continue to expand as federally funded re-
search at academic centers faces massive cuts [1]. In 2000,
70% of the clinical drug trial enterprise was funded by
industry rather than by the National Institutes of Health
(NIH), and as of 2010 this proportion is increasing [2,3].
Pharmaceutical companies fill a critical need by providing
substantial upfront investment in the drug development
process. This is particularly evident with chronic diseases
that may have a low event rate over a long period of time.
It is, however, axiomatic that business interests are a
primary consideration in this process, and generation of
profits over time is thus a central necessary theme. This
may not always align with the goal of identifying the most
effective treatments that maximize public health [4,5].
Ross and colleagues document some techniques that
industry has used to tilt the research framework in their
favor, including seeding trials, inappropriate authorship,
market-driven publication planning, and selective publica-
tion and reporting [6].
The role of industry in HIV trials is particularly interest-
ing as HIV has evolved into a chronic comorbidity, rather
than a death sentence, with high profits for manufacturers
of lifelong, well-tolerated antiretrovirals. Hepatitis C (HCV)
has also recently attracted attention from industry; in
the past decade, three major anti-HCV agents have gone
through the Food and Drug Administration (FDA) sub-
mission process, supported by trials with sponsorship
from both industry and academic-based groups. A scar-
city of data exists, however, on the potential influence of
industry sponsorship on infectious diseases (ID) studies,
given that industry has traditionally been less likely than
government to conduct HIV and other virus-related re-
search due to the public health, rather than market-
driven, nature of these infections [7,8].
Prior epidemiology studies have compared several
characteristics of general industry-sponsored versus
non-industry-sponsored trials, including the following: (1)
methods of subject recruitment [5]; (2) outcomes favoring
the investigational drug [9-13]; (3) reporting and publication
timing of outcomes and adverse drug events [5,6,12,14-16];
(4) affiliations of publication authors [12,17]; and (5) reasons
for early study termination [11,18,19]. These studies, how-
ever, have generally been limited to the published literature,
sometimes to a few core journals, rather than evaluating all
trials registered in a public database, and therefore may not
be capturing the full extent of potential industry-related bias.
While limited data exists for ID, and HIV and HCV trials in
particular, recent data suggests sponsors of industry-funded
ID trials are more likely to add, omit, or reclassify outcomes
compared to other specialties, and are more susceptible to
publication bias [20,21]. ID trials have been less studied, inpart because there are not dedicated ID trial registries,
and also because some ID fields, such as HIV and HCV,
have received only intermittent waves of new promising
therapies. This differs from the field of oncology, where
new agents are constantly undergoing evaluation by the
FDA, and potential differences in methodology between
trials based on trial sponsorship have been extensively
scrutinized [19].
The aim of this study was to evaluate if industry-
sponsored HIV/AIDS and HCV drug intervention trials
entered in a public registry were less likely to use a
randomized study design than non-industry-sponsored
trials, after adjustment for presence of a data monitoring
committee, anticipated or actual enrollment, number of
study sites, inclusion of foreign study sites, exclusion of
persons older than age 65, and disease condition. We also
evaluated if this relationship differed based on study phase
since phase 4 trials, generally conducted after FDA drug
approval, may be less influenced by federal regulations than
phase 2 and 3 trials.
Methods
In this cross-sectional study, we analyzed data from
trials registered in the ClinicalTrials.gov registry from
2007 through 2010 to study the association between
industry sponsorship of interventional trials and ran-
domized study design.
Data source
To address concerns related to study design and publi-
cation bias, the FDA mandated public registration of
all trials of drugs, biologics, or devices intended for
FDA submission with penalties for non-compliance in
2007. The International Committee of Medical Journal
Editors (ICMJE) also implemented a policy requiring
prospective registration of phase 2 to 4 trials for publica-
tion in member journals. ClinicalTrials.gov is the largest
US-based database of its kind that allows investigators to
fulfill these mandates and covers a full range of clinical
conditions as well as a broad group of trial sponsors [22].
Transformation of the registry database into a research
dataset (Aggregate Analysis of ClinicalTrials.gov) by the
Clinical Trials Transformation Initiative (CTTI), a col-
laboration between the FDA and Duke University, pro-
vides the opportunity for critical evaluation of study
designs for industry-sponsored trials, independent of
publication status. The methods used by ClinicalTrials.
gov to register clinical trials have been described previously
[22]. Briefly, trial sponsors and investigators from around
the world can enter trial data through a web-based data
entry system.
The ID interventional clinical trials sub-dataset was
created in 2011 to describe trial methodology, geographic
distribution, and funding source of current ID trials [23]
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from 1 October 2007 to 27 September 2010. As part of this
study, trials were subcategorized into content areas based
on study title and description. A total of 58 categories were
defined, including HIV-AIDS; HCV; lower respiratory tract
infection (LRTI); hepatitis B; malaria; diarrheal diseases;
sexually transmitted diseases (STD) excluding HIV; tu-
berculosis; childhood cluster diseases; and meningitis.
Study design
From the ID dataset, we conducted a cross-sectional ana-
lysis of 774 HIV and HCV drug intervention clinical trials.
Interventional trials involving a procedure, vaccine, behav-
ioral intervention, or device were not included. Since our
target analysis was for adult-only trials, we excluded trials
that included children (age less than 18 years old). We ex-
cluded all nonhuman preclinical trials, phase 0 pharmaco-
kinetic/pharmacodynamics trials, and phase 1, phase 1/2
dose escalation studies, as these by definition are single
arm studies without a randomized study design (Figure 1).Trials in CT.GOV database 
downloaded September 27, 2010
(n = 96,346)
Trials after non-interventional and out 
of date range removed
(n=40,970)
Trials manually categorized as 
infectious disease trials
(n = 3,570)
HIV and hepatitis 
C drug trials 
(n= 774)
Adult HIV and 
hepatitis C trials
(n= 747)
Exclud
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Figure 1 Trial selection from the ClinicalTrials.gov registry, 2007 to 20
clinical trials was identified for cross-sectional analysis.Studies in which a phase was reported as ‘Not applicable’
were also excluded.
Variable definitions
The primary exposure, industry sponsorship, was derived
from lead sponsor, a nominal categorical variable reported
by trial investigators and coded dichotomously. In the
web-based data entry system, lead sponsor was described
as the primary organization that oversees study imple-
mentation and is responsible for conducting data analysis.
Outcome was randomized (versus non-randomized) study
design and was reported by sponsor on the ClinicalTrials.
gov data entry website. Randomization was chosen as the
outcome since choice of this design would be most likely
to yield unbiased results. Based on prior studies of registry
clinical trials and potential associations with the exposure
and outcome, the following covariates were analyzed: trial
status, enrollment sample size (anticipated or actual), study
start year, study phase, presence of a data monitoring
committee, exclusion of persons older than age 65, numbere trials with 
pants <18 years
)
e preclinical, phase 0, 1 trials, and 
here phase reported as “N/A”
0)
10. A sub-group of 774 HIV and hepatitis C virus (HCV) drug intervention
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study sites.
For active studies that had not completed recruitment,
data entrants recorded anticipated enrollment. For studies
that had completed or terminated recruitment, actual
enrollment was reported. Enrollment was reported in
the original dataset as a continuous variable. Based on
prior literature describing trial size in pre-specified
categories [22], data was assigned into the following
categories: less than or equal to 100, 101 to 1,000, and
greater than 1,000 participants. Study start year was
available in the original dataset for both future trials
(anticipated start year) and completed trials (actual
start year). As our analysis focused on the 2007 to 2010
time frame, earlier studies were consolidated into a
‘Prior to 2007’ category and values for the remaining
observations were maintained. Location of study facilities
(sites) was defined by the study sponsor and could include
more than one location for multi-site studies. This infor-
mation was used to determine if the study included non-
US sites. Number of study sites was reported as multi-site
versus single site.
Statistical analysis
Summary statistics were calculated by pooling across active
and completed studies. To control for multiple variables
simultaneously, we carried out multivariable Poisson re-
gression analysis to calculate prevalence ratio (PR) esti-
mates. These models included industry sponsorship as the
primary exposure, randomization use as the outcome, and
all factors statistically associated either in the literature or
in our univariate models with randomized study design.
Effect measure modification was assessed by using a
likelihood ratio (LR) test to compare the fully-adjusted
model (which included the product term for industry
sponsorship by study phase) to a nested model with the
product term removed. An a priori criterion of P < 0.15
was used to determine whether it was necessary to in-
clude the interaction term. Colinearity of similar vari-
ables was evaluated with Pearson’s correlation testing;
for variables with a Pearson’s coefficient (r) ≥ 0.7, only
the more relevant variable was included. SAS software,
version 9.2 (SAS Institute, Cary, NC, USA) was used for
all statistical analyses.
Power calculation
The study required a sample of 366 trials to achieve 80%
power, assuming that 65% of registered trials from non-
industry sponsors would use randomization and 50% from
industry sponsors.
Procedures for the ethical conduct of research
The protocol for this study was reviewed and declared
as exempt by the University of North Carolina (UNC)School of Public Health Institutional Review Board (IRB),
Protocol Number 119879.
Results
A total of 477 HIV and/or HCV adult interventional clinical
drug trials were included, with 304 (64%) HIV/AIDS trials,
156 (33%) HCV trials, and 17 (4%) co-infection trials.
Trial characteristics are shown in Table 1. Our sample
included 179 (38%) industry-sponsored trials and 298
(63%) non-industry-sponsored trials. Most non-industry
trials were sponsored by academic institutions or hospitals
(Table 2). Of the 469 trials with reported allocation data,
329 (69%) had a randomized study design and 140 (29%)
were non-randomized. The majority of studies were ac-
tively recruiting or had completed recruitment of partici-
pants (n = 300, 63%), while the remainder either were not
recruiting at the time of analysis (n = 164, 34%) or had
undergone study termination (n = 13, 3%). Most inter-
ventional HIV and HCV trials were small, with a me-
dian anticipated or actual sample size of 80 persons
(interquartile range (IQR): 36, 179), and 288 (60%) tri-
als with 100 participants or less.
This dataset focused on trials registered between 2007
to 2010, and most studies had a start date of 2008 or
later; only 63 (13%) started before 2007. Overall, more
studies were phase 2 or 3 (n = 284, 60%) rather than
phase 4 (n = 193, 41%) and about 40% (n = 189) utilized
a data monitoring committee (DMC). Exclusion of elderly
(persons older than 65 years old) was uncommon in
our studies; 352 (74%) of studies did not report this as
an exclusion criteria. A similar proportion of studies
were single-site studies (43%, n = 205) as compared to
those that included multiple sites for recruitment of
participants (47%, n = 225). All interventional trials
with at least one US site are required by the FDA to be
reported in a public registry, [22] but most HIV/hepatitis
studies (n = 351, 74%) also included foreign sites.
All variables had fewer than 15% observations with
missing data in this dataset except for reporting of a DMC,
for which 81 trials (17%) had a missing value. In a multivari-
able predictive model for missing DMC data, missing was
not associated with use of randomization, actual/anticipated
enrollment, study phase, trial exclusion of elderly persons,
number of sites, inclusion of foreign study sites, or disease
condition. Trials missing DMC data were more likely to be
industry-sponsored (PR = 4.03, 95% CI 2.05, 7.92) than
trials not missing data on use of a DMC.
Effect measure modification was not found to be statisti-
cally significant by study phase (phase 2/3 versus phase 4,
P = 0.30. In stratified tabular analysis the adjusted PR was
1.14 (95% CI 0.78, 1.68) among phase 2/3 trials and 1.06
(95% CI 0.50, 2.22) among phase 4 trials. Interaction was
also not significant for disease condition (HIV/AIDS versus
HCV, P = 0.84), or use of a DMC (P = 0.54).
Table 1 Characteristics of eligible HIV/Hepatitis C
interventional trials, ClinicalTrials.gov registry, 2007 to
2010 (N = 477)
Characteristic N % or IQR
Primary Sponsor
Non-industry 298 62.5
Industry 179 37.5
Allocationa
Non-Randomized 140 29.4
Randomized 329 69.0
Overall status
Not yet recruiting 41 8.6
Recruiting 206 43.2
Active not currently recruiting 123 25.8
Completed 94 19.7
Terminated 13 2.7
Number of participantsa
Median (IQR) 80 36, 179
Less than or equal to 100 288 60.4
101 to 1,000 173 36.3
Greater than 1,000 14 2.9
Start yeara
Before 2007 63 13.2
2007 42 8.8
2008 130 27.3
2009 137 28.7
2010 98 20.6
Phase
2/3 284 59.5
4 193 40.5
Study has DMCab
No 207 43.4
Yes 189 39.6
Excludes > 65 years
No 352 73.8
Yes 125 26.2
Number of study sitesa
Single facility 205 43.0
Multiple facilities 225 47.2
Foreign sites
No 126 26.4
Yes 351 73.6
Condition
Hepatitis C (HCV) 156 32.7
HIV/AIDS 304 63.7
HCV + HIV/AIDS 17 3.6
aTotals for each variable may not add up to 100 % secondary to observations
with missing data.
bDMC = data monitoring committee. IQR = interquartile range.
Table 2 Sponsors of eligible HIV/Hepatitis C interventional
trials, ClinicalTrials.gov registry, 2007 to 2010 (N = 477)
Sponsor N %
Industry 179 37.5
NIH 18 3.8
US Federal 5 1.1
Government-Foreign 24 5.0
Academic/Hospital 179 37.5
Consortium 30 6.3
Other 72 8.8
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sites, inclusion of foreign sites, and disease condition were
associated with industry sponsorship (Table 3). Industry-
sponsored trials were more likely to have large sample
sizes (100 to 1,000 participants) than small sample sizes
(less than or equal to 100 participants, PR = 1.76, 95% CI
1.31, 2.38), multi-center rather than single center studies
(PR = 4.25, 95% CI 2.74, 6.61), and include foreign sites
(PR = 2.21, 95% CI 1.45, 3.37). Industry trials were less likely
to be HIV/AIDS trials than HCV trials (PR = 0.39, 95% CI
0.29, 0.53) and also less likely to be phase 4 trials than
phase 2 or 3 (PR = 0.25, 95% CI 0.16, 0.38). The covariates
we analyzed were not significantly associated with use of
randomized study design in this sample (data not shown).
We found that use of randomization was as likely in
registered industry-sponsored trials as in non-industry-
sponsoreded trials (Table 4, PR 1.17, 95% CI 0.94, 1.45).
This persisted even after adjusting for other characteris-
tics associated with choice of randomized study design,
including presence of a DMC, study phase, sample size,
number of study sites, inclusion of foreign study sites,
exclusion of persons older than age 65 and disease condi-
tion (PR = 1.13, 95% CI 0.82, 1.56).
Discussion
Our data suggests that in registered HIV and HCV trials,
regardless of publication, randomization is not significantly
differentially utilized by industry, and is not a clear mani-
festation of industry bias. The goal of mandated public trial
registration is to reduce bias by allowing increased crit-
ical evaluation of trial design and to encourage full
outcome reporting. Our analysis is one of a recent few
that have looked at trends in registered trials to see if
registration may be meeting this goal, facilitated by the
CTTI-initiated ClinicalTrials.gov transformation into a
research dataset. While some authors suggest industry
trials may manipulate study methodology to report a
desired outcome or achieve other goals, other academics
suggest that industry trials may actually have the same
or higher standards for methodological quality because
of closer scrutiny [5,11,24,25].
Table 3 Association between trial characteristics and industry sponsorship in eligible HIV/Hepatitis C interventional
trials, ClinicalTrials.gov registry, 2007 to 2010 (N = 477)
Characteristic Industry-sponsored Non-industry-sponsored PRc 95% CI
Number of participantsa
Median (IQR) 120 (50,290) 60 (30,140)
Less than or equal to 100 84 204 1.0
101 to 1,000 89 84 1.76 1.31, 2.38
Greater than 1,000 5 9 1.22 0.50, 3.02
Start yeara
Before 2007 24 39 1.0
2007 16 26 1.0 0.53, 1.88
2008 55 75 1.11 0.69, 1.79
2009 52 85 1.0 0.61, 1.62
2010 30 68 0.80 0.47, 1.37
Phase
2/3 153 131 1.0
4 26 167 0.25 0.16, 0.38
Study has DMCab
No 69 138 1.0
Yes 52 137 0.83 0.58, 1.18
Excludes > 65 years
No 128 224 1.0
Yes 51 74 1.12 0.81, 1.55
Number of study sitesa
Single facility 24 181 1.0
Multiple facilities 112 113 4.25 2.74, 6.61
Foreign sites
No 25 101 1.0
Yes 154 197 2.21 1.45, 3.37
Condition
Hepatitis C (HCV) 99 57 1.0
HIV/AIDS 76 228 0.39 0.29, 0.53
HCV + HIV/AIDS 4 13 0.37 0.14, 1.01
aTotals for each variable may not add up to N = 468 secondary to observations with missing data.
bDMC = data monitoring committee.
cPR = unadjusted prevalence ratio, calculated from Poisson regression model with covariate as exposure and industry sponsorship as outcome.
IQR = interquartile range.
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clinical research, but there are ways within randomized
trials to introduce bias, and this should be further scruti-
nized in comparing ID trials with different sponsors.
Previous authors have evaluated the use of blinding,
selection of sample size, choice of comparator, analytic
methods, partial versus full reporting of outcomes, and
agreement between results and conclusions in industry-
sponsored trials, providing some evidence for industry bias
[6,14,26-28]. Lathyris, et al. for example, found that
companies are more likely to choose only their own
products as comparators rather than conducting moremedically appropriate head-to-head trials with drugs from
different companies [26], and other studies describe phar-
maceuticals choosing placebo or a suboptimal agent when
an effective comparator exists [27].
Randomized HIV and HCV trials may also not be
the best option for some situations where the number
of patients under study is too few and other designs,
such as crossover trial designs, are more appropriate.
Randomization is furthermore not essential in situa-
tions of clinical ‘equipoise’, when the optimal standard
of care is unclear. Study design is also only one step in the
clinical trial inception and implementation cascade, and
Table 4 Unadjusted and adjusted prevalence ratios for
use of randomization with industry and non-industry
sponsors in eligible HIV/Hepatitis C interventional trials,
ClinicalTrials.gov registry, 2007 to 2010 (N = 468)
Sponsor Prevalence ratio 95% CI
Unadjusted: 1.17 0.94, 1.45
Industry sponsor
Adjusted:a 1.13 0.82, 1.56
Industry sponsor
aBased on Poisson regression model, adjusted for presence of a data
monitoring committee, enrollment size, study phase, number of study sites,
inclusion of foreign study sites, exclusion of persons older than age 65, and
disease condition.
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tion. We chose to focus on randomization as a methodo-
logic choice, but prior studies have shown that sponsor
bias may influence other downstream steps in the process
[5,6,10,12-14]. The most relevant final action susceptible
to sponsor bias is physicians’ use of evidence-based
medicine after study publication, which has been the
major target of the Patient Protection and Affordable Care
Act’s Physician Payment Sunshine provision [6].
The major limitations to our study were the fact that
all trial data was self-reported by study sponsors, rather
than determined by an objective third party, and that
unregistered trials were not included, similar to other
analyses using the ClinicalTrials.gov database [29]. The
registry also does not provide a means to assess the
strength of the randomization process in any study.
We furthermore measured industry involvement in trials
by sponsorship, rather than by industry funding or author
affiliation with industry, given that the latter are not
directly reported in ClinicalTrials.gov. Given that many
non-industry-sponsored trials may receive industry funding
at some level and therefore be susceptible to some
amount of industry bias, it is possible that we underes-
timated the association between industry involvement
and use of randomization.
Our study also focused on trials registered with
ClinicalTrials.gov, one of several registries where trials
can be reported, including the International Standard Ran-
domized Control Trial Number Register (http://isrctn.org),
World Health Organization (WHO) International Clinical
Trials Registry (www.who.int/trialsearch/), and corporate
trial registries and databases of manufacturers of drugs.
ClinicalTrials.gov is the largest US-based registry, however,
and may be generalizable for all registered HIV and HCV
interventional trials.
Given that trials cannot be registered without completion
of all mandatory data elements and are required to conform
to relevant national health regulations, we had few missing
data. For the one variable that did have a significant per-
centage of missing data, utilization of a data monitoringcommittee, our analysis showed this was more likely to go
unreported in industry- sponsored trials. This could be
explained by other arrangements for safety monitoring
in industry trials besides the use of DMC, such as use
of a contract ethics review board.
We expected to see a stronger association of industry
sponsorship and decreased use of randomization in phase
4 HIV and HCV trials (compared to phase 2 and 3 trials),
since these are conducted after FDA drug approval and
therefore generally have less governmental oversight.
Phase 4 registered trials on ClinicalTrials.gov have also
been shown previously to report less use of blinding
and randomization overall [22]. Effect measure modifica-
tion was not significant in our analysis, however. This could
be due to the fact that post-registration HIV/AIDS and
HCV trials sponsored by industry are more likely to
collaborate with academic institutions and consortia
than other disease conditions, or are under more public
scrutiny overall.
Conclusions
In this cross-sectional analysis of publicly registered
HIV/AIDS and HCV adult phase 2 to 4 interventional
clinical trials, we found randomized study design was
as likely in industry-sponsored trials as in non-industry-
sponsored trials. The potential for industry bias in the full
cascade of publicly registered trials, from study design to
implementation and presentation, though, requires further
critical evaluation.
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